RUNX1 and acute myeloid leukemia: Thyrotropin-releasing hormone (TRH), one of the biomarkers for CD34+CD117bri myeloblasts, was observed to be highly expressed in AML patients, especially in those with RUNX1-RUNX1T1 AML [9].